F11R Antikörper (Extracellular Domain) (FITC)

Produktnummer ABIN1106269

Dieses Maus Monoklonal-Antikörper erkennt spezifisch F11R in WB, FACS, IF und IHC (fro). Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für F11R Antikörper (Extracellular Domain) (FITC) (ABIN1106269)

Target: F11R (F11 Receptor (F11R))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser F11R Antikörper ist konjugiert mit FITC

Applikation: Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Frozen Sections) (IHC (fro))

Klon: BV16

Produktdetails anti-F11R Antikörper (FITC)

Bindungsspezifität: Extracellular Domain

Spezifität: The monoclonal antibody BV16 recognizes the human junction adhesion molecule (JAM)-A.

Kreuzreaktivität (Details): Species reactivity (tested):Human

Aufreinigung: Potein G

Immunogen: Fusion protein consisting of the extracellular domain of human JAM and the Fc portion of human IgGs

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.1 mg/mL

Buffer: PBS, 0.02 % sodium azide, 1 % bovine serum albumin

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Prior to reconstitution store at 2-8 °C. Following reconstitution store undiluted at 2-8 °C for one month or or (in aliquots) at -20 °C for longer.

Details zu F11R

Target: F11R (F11 Receptor (F11R))

Andere Bezeichnung: CD321 / JAM1

Hintergrund: Together with JAM-C (JAM-2) and JAM-B (VE-JAM or JAM-3), JAM-A belongs to a family of adhesion proteins with a V-C2 immunoglobulin domain organization and their molecular weight is about 30-40 kDa. JAMs are important for a variety of cellular processes, including tight junction assembly, leukocyte transmigration, platelet activation, angiogenesis and virus binding. JAM-A is expressed by endothelial and epithelial cells, platelets, neutrophils, monocytes, lymphocytes and erythrocytes. Like all other JAMs, JAM-A plays an important role in tight junctions where it is involved in cell-to-cell adhesion through homophilic interaction. It codistributes with other tight junction components as ZO-1, 7H6 antigen, cingulin and occludin. JAM-A also plays an important role in leukocyte transmigration. Leukocyte transmigration can be blocked by antibodies and by soluble JAM-A/Fc fusion proteins. Homophilic JAM-A interactions between leukocytes and the endothelium but also heterophilic interactions of JAM-A with the beta2-integrin leukocyte function-associated antigen-1 (LFA-1) are considered to actively guide leukocytes during transmigration. Several studies imply a role for JAM-A in the initiation of atherosclerosis since JAM-A is upregulated on early atherosclerotic endothelium. The adhesion of activated platelets on the activated endothelium is mediated by homophilic interactions of JAM-A.Synonyms: F11R, JAM-A, JCAM, Junctional adhesion molecule 1, Junctional adhesion molecule A, PAM1, Platelet F11 receptor, Platelet adhesion molecule 1

Gen-ID: 50848

NCBI Accession: NP_058642

UniProt: Q9Y624

Pathways: Cell-Cell Junction Organization